NEW YORK – Myriad Genetics said Tuesday that it has entered a new collaboration with Flatiron Health, a Roche company, that will make its MyRisk hereditary cancer test available for physicians to order through Flatiron's cloud-based electronic medical record system OncoEMR.
According to Myriad, the OncoEMR network serves 4,200 providers at over 800 community-based cancer care locations across the US. MyRisk is the first hereditary cancer test to be incorporated into OncoEMR.
Myriad Chief Clinical Officer of Oncology George Daneker said in a statement that the integration is intended to help simplify the ordering experience for clinicians in Flatiron's network. The company anticipates adding other tests in the future.
Financial terms of the partnership were not disclosed.
Other firms offering their tests through Flatiron's EMR portal include Caris Life Sciences and Guardant Health.